Response Rate - the proportion of subjects with objective response based on RECIST criteria A minimum of 13 weeks (time to first follow-up CT) [clinicaltrials_resource:45fe149f3ac78894e616b43c01d8f74c]
1.2mg in combination with adjuvant GPI-0100 administered subcutaneously (beneath the skin) weekly for 4 consecutive weeks during the first cycle of treatment, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Response Rate - the proportion of subjects with objective response based on RECIST criteria A minimum of 13 weeks (time to first follow-up CT) [clinicaltrials_resource:45fe149f3ac78894e616b43c01d8f74c]
1.2mg in combination with adjuvant GPI-0100 administered subcutaneously (beneath the skin) weekly for 4 consecutive weeks during the first cycle of treatment, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
Bio2RDF identifier
45fe149f3ac78894e616b43c01d8f74c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:45fe149f3ac78894e616b43c01d8f74c
measure [clinicaltrials_vocabulary:measure]
Response Rate - the proportion ...... ponse based on RECIST criteria
time frame [clinicaltrials_vocabulary:time-frame]
A minimum of 13 weeks (time to first follow-up CT)
description
1.2mg in combination with adju ...... nce for each additional cycle.
identifier
clinicaltrials_resource:45fe149f3ac78894e616b43c01d8f74c
title
Response Rate - the proportion ...... s (time to first follow-up CT)
@en
type
label
Response Rate - the proportion ...... e149f3ac78894e616b43c01d8f74c]
@en